OverviewChartTechnicalNewsTraderScreen

Cellectis SA/  FR0010425595  /

Euronext - Paris
2024-10-04  5:35:26 PM Chg. -0.004 Volume Bid5:40:00 PM Ask5:40:00 PM High Low
1.808EUR -0.22% 54,097
Turnover: 97,275.772		 1.760Bid Size: 200 1.840Ask Size: 200 1.822 1.758
GlobeNewswire 08-26 Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Rec...
GlobeNewswire 08-08 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First...
GlobeNewswire 08-07 Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update 
GlobeNewswire 08-07 Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
GlobeNewswire 08-06 Cellectis Provides Financial Results for the Second Quarter 2024
GlobeNewswire 08-01 FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
GlobeNewswire 07-25 FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product c...
GlobeNewswire 07-16 Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as D...
GlobeNewswire 07-01 Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase ...
GlobeNewswire 06-28 Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
GlobeNewswire 06-20 Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
GlobeNewswire 06-20 Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cem...
GlobeNewswire 06-12 Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
GlobeNewswire 06-04 Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients wi...
GlobeNewswire 05-29 Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
GlobeNewswire 05-28 Cellectis Reports Financial Results for First Quarter 2024
GlobeNewswire 05-27 Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
GlobeNewswire 05-13 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
GlobeNewswire 05-09 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire 05-06 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire 05-02 Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
GlobeNewswire 04-29 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
GlobeNewswire 04-26 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advan...
GlobeNewswire 04-22 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene...
GlobeNewswire 04-10 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Dis...